☆ 4.4 Article

Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study

LANCET HAEMATOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Allison Barz Leahy et al.

Summary: Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed/refractory B-acute lymphoblastic leukemia (ALL), regardless of different cytogenetic characteristics. High-risk patients, including those with KMT2A-rearranged infant ALL, showed high probabilities of relapse-free survival and overall survival at 2 years.

BLOOD (2022)

Add to Collection

Article Oncology

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report

Liora M. Schultz et al.

Summary: Commercial tisagenlecleucel demonstrates efficacy and tolerability in patients with relapsed and refractory B-ALL. The study finds that high disease burden is associated with inferior overall survival, event-free survival, and increased toxicity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

Regina M. Myers et al.

Summary: This retrospective study investigates the impact of CD19-CAR therapy on relapsed or refractory ALL patients, revealing that nonresponse to blinatumomab and high disease burden are associated with worse survival outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Hematology

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Swantje Buchmann et al.

Summary: Comparison of treatment strategies in de novo pediatric acute lymphoblastic leukemia (ALL) requires standardized measures of efficacy. Key parameters defining disease-related events, such as complete remission (CR), treatment failure (TF), and relapse, have significant heterogeneity in their definitions. A consensus definition was established by representatives of major international ALL clinical trial groups, which includes specific criteria for CR, TF, and relapse. These consensus definitions will improve the comparability of outcomes in pediatric ALL trials and promote the development of international collaborative trials.

BLOOD (2022)

Add to Collection

Article Hematology

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia

Amy Moskop et al.

Summary: This study retrospectively evaluated the use of CD19-directed CAR-T therapy Tisagenlecleucel in infants with B-ALL and found that it is safe and potentially effective in this population.

BLOOD ADVANCES (2022)

Add to Collection

Meeting Abstract Hematology

A Phase 2 Study to Test the Feasibility Safe and Efficacy of the Addition of Blinatumomab to the Interfanto6 Backbone in Infants with Newly Diagnosed KMT2A-Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network

Inge M. Van Der Sluis et al.

BLOOD (2021)

Add to Collection

Article Oncology

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Marie-Emilie Dourthe et al.

Summary: Tisagenlecleucel therapy has shown promising efficacy in relapsed/refractory BCP-ALL patients, with a high complete remission rate at D28. However, factors such as prior therapy and disease burden can impact the risk of relapse and overall survival. Detectable MRD at D28 and loss of BCA may define patients at high risk of relapse, requiring additional interventions.

LEUKEMIA (2021)

Add to Collection

Article Hematology

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham et al.

BLOOD (2020)

Add to Collection

Article Hematology

A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial

Daisuke Tomizawa et al.

BLOOD (2020)

Add to Collection

Meeting Abstract Hematology

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Sara Ghorashian et al.

BLOOD (2020)

Add to Collection

Article Hematology

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Marcelo C. Pasquini et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Oncology

Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study

Rob Pieters et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Hematology

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley et al.

BLOOD (2019)

Add to Collection

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Hematology

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Vinodh Pillai et al.

BLOOD ADVANCES (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Letter Oncology

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol

E. M. C. Driessen et al.

LEUKEMIA (2016)

Add to Collection

Article Hematology

Lineage switch in childhood acute leukemia: An unusual event with poor outcome

Jorge G. Rossi et al.

AMERICAN JOURNAL OF HEMATOLOGY (2012)

Add to Collection

Article Medicine, General & Internal

A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial

Rob Pieters et al.

LANCET (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.